Tyndall makes strides in colon cancer diagnoses and treatment
Research into new biophotonics technology for disease detection and surgical guidance receives international acclaim
Researchers in the IPIC SFI Research Centre for Photonics at Tyndall National Institute are developing a more effective and less invasive way to diagnose and treat colorectal cancer, which is the third most common type of cancer in the world and the second most deadly, in partnership with clinicians at Mercy University Hospital (MUH) and Cork University Hospital (CUH).
They have created a tool for non-invasive surgical guidance and early disease detection using biophotonics technology, a light-based instrument that senses and differentiates tissues more accurately and faster.
The team’s research has just been published in the Nature journal, Scientific Reports, describing how the use of biophotonics can help to radically improve health outcomes for patients as it is a less invasive method and provides more comprehensible information to clinicians and surgeons in real-time, particularly in the area of colon cancer.
Pre-clinical and clinical studies with patients who have gastrointestinal diseases and oral cancer are expected to commence in the MUH and CUH in late 2021.
Commenting, Marcelo Saito Nogueira from the Biophotonics team said, “Clinical interventions have been significantly improved by recent advances in devices for diagnostics and surgical guidance. However, most of the current imaging technologies provide primarily tissue morphological and/or structural information, which is only detectable at a late stage in the disease. The tools we are developing will be more beneficial as they identify and locate disease at an earlier stage based on molecular changes, If accurately detected, the disease can be fully treated in less procedures, and the risk to the patient and number of cancer surgeries would be reduced.”
“Optical spectroscopy and imaging techniques are promising molecular-sensitive tools with potential to monitor diseases and guide surgical procedures by providing a non-invasive, fast and in situ interrogation of biological tissues. We have shown that by selecting fine wavelengths of light it is possible to differentiate the molecular structure of cancerous versus non-cancerous cells. These techniques can be cost-effective and integrated into existing clinical tools, which enhances their potential to improve the current healthcare system and also makes them commercially attractive. We also look forward to collaborating in the future with one of the numerous medical device companies located in Ireland.”.
Colon cancer accounts for more than 9% of all cancer deaths worldwide and this is estimated to increase by 71.5% by 2040. The projected increased incidence of colon cancer and the improvement on patient prognosis generated by early colon cancer detection has expedited interest in the development of novel techniques to detect precancerous and cancerous lesions early.
The Biophotonics team at Tyndall, at UCC, is researching non-invasive techniques that are more accurate and faster than conventional detection methods. Following the initial positive results that validate the idea, they are now developing a probe for colon cancer detection during colonoscopy, which can investigate additional types of biomolecules located at different tissue depths by using extended wavelength range.
This technology will help surgeons to take biopsies at the right places, as currently they have no guidance as to where to request a biopsy, which will obviate the need for multiple biopsies or polypectomies. It could also help identify more subtle abnormalities such as premalignancies invisible through colonoscopes and medical devices.
Further information on Tyndall’s biophotonics teams’ research into colorectal diagnoses and treatment can be seen in Scientific Reports ‘Evaluation of wavelength ranges and tissue depth probed by diffuse reflectance spectroscopy for colorectal cancer detection.’